Monday, September 28, 2026
BTC $83,126 ▼ 0.40%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.246down−0.43%ETH$2,675down−0.47%LINK$15.38down−0.42%SOL$118.03down−0.67%BTC$83,126down−0.40%XRP$1.49down−0.54%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,150.40down−0.43%SILVER$61.06down−1.07%OIL$93.30up+0.76%DXY101.23up+0.03%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — GreedADA$0.246down−0.43%ETH$2,675down−0.47%LINK$15.38down−0.42%SOL$118.03down−0.67%BTC$83,126down−0.40%XRP$1.49down−0.54%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,150.40down−0.43%SILVER$61.06down−1.07%OIL$93.30up+0.76%DXY101.23up+0.03%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — Greed
Tag

clinical trials

1 article

Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Research & Analysis40d ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.